PIONEERING HEMATOLOGIC MALIGNANCY DISCOVERIES and Turning Research into Innovative Treatment
Discover our latest advances at the all-virtual ASH Annual Meeting December 5-8 , 2020
City of Hope is a leader in cancer research , clinical treatment and patient care . We strive to bring innovations in hematologic cancer treatment , stem cell transplant and CAR T cell therapy into early stage clinical trials , ultimately translating into effective treatments .
Helping lead the way in stem cell transplant
• Over 16,000 transplants performed
• The only institution in the nation to exceed survival rate expectations of CIBMTR for 15 consecutive years *
• Expanding the possibilities of transplant – 720 annual transplants , on average
– Nearly 300 haploidentical transplants in last 5 years
– One of the first to perform bone marrow transplants in patients over age 70
– Pioneering the efficacy of transplant for patients with HIV and lymphoma
The forefront of CAR T cell therapy
• Over 500 patients treated in over 45 CAR T cell trials ( current or completed ), targeting both solid tumors and hematologic malignancies
• One of the first to offer both FDA-approved commercial therapies , axicabtagene ciloleucel ( Yescarta ) and tisagenlecleucel ( Kymriah )
• Onsite CAR T cell engineering and manufacturing in our GMP facilities
• Pioneering CAR T cell therapy as a bridge to transplant for patients with leukemia and lymphoma
* Center for International Blood and Marrow Transplant Research .
Consider City of Hope for your patients Find out more at CityofHope . org or call 800-COH-4DRS
Recognized as One of the Nation ’ s Best Hospitals for 14 Consecutive Years by U . S . News & World Report